Pediatric Praziquantel Consortium

Consortium intensifies its focus on future access

11 October 2019

In September the Levo-Praziquantel 150mg Phase 3 trial was initiated in Kenya. With the project moving towards...

From the Program Lead: The Consortium has started the Phase III trial and is preparing for access

18 September 2019

The pivotal phase III study with the L-praziquantel pediatric oral dispersible tablets (ODTs) has started, shortly...

A new formulation to fight Schistosomiasis

A pediatric formulation of Praziquantel has been developed for schistosomiasis.
Video credits: The GHIT Fund


Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more


Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

The consortium established a pediatric drug development program, divided into three major steps: preclinical development, clinical development and registration and access.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more